Sprycel 70mg Tablet

Sprycel may cause some common side effects. Before starting treatment, discuss the risks and benefits of Sprycel tablets, as well as your medical history, with your doctor. 

• Bleeding gums  
• Constipation  
• Coughing up blood  
• Body pain  
• Dizziness  
• Weight gain  
• Irregular heartbeat  
• Sore throat 
• Headache  
• Nasal congestion  
• Anemia  
• Fatigue  
• Nausea  
• Infection  
• Low blood platelets 

Take Sprycel 70mg Tablet as prescribed by your doctor. Do not stop or skip your regular dosing schedule.  In case of an overdose of Sprycel tablets, the doctor will provide emergency medical treatment. 

Acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML) cell lines that overexpressed BCR-ABL were reduced in their proliferation by dasatinib. Dasatinib successfully overcame imatinib resistance caused by mutations in the BCR-ABL kinase domain, activation of alternative signaling pathways involving the SRC family kinases (LYN, HCK), and overexpression of multi-drug resistance genes under the assay conditions. The effects of this medication can be seen one to six hours after oral consumption.

It is advisable not to miss a dose. If you miss a scheduled dose of Sprycel tablets, contact your doctor immediately.  

At our pharmacy, your health is our top priority. All of our medicines are safe, effective, and approved by leading health authorities. We partner exclusively with reliable and reputable manufacturers, ensuring the highest quality standards in every product we deliver.

Enjoy the convenience of fast home delivery, secure packaging, and affordable prices*—plus *special discounts on bulk orders. We’re proud to offer international shipping to a wide range of countries across Asia, Europe, Africa, the Americas, and beyond, making trusted healthcare accessible no matter where you are.

Whether you're a patient or a healthcare provider, you can order with confidence and compassion. Our goal is to ensure that quality healthcare reaches everyone, everywhere.

We Currently Ship To:

Barbados, Haiti, Trinidad and Tobago, Mexico, Bahamas, Ecuador, Peru, Chile, Brazil, Colombia, Philippines, U.K., USA, Kuwait, Saudi Arabia, UAE, Oman, Qatar, Japan, Ireland, Russia, China, France, Australia, Lithuania, Nigeria, Romania, Algeria, Canada, Singapore, Thailand, Hong Kong, Bahrain, Jordan, Indonesia, Hungary, Moldova, Bulgaria, Azerbaijan, Congo, Ethiopia, Lebanon, Morocco, Mozambique, South Korea, Sri Lanka, Belarus, Mongolia, Malaysia, Vietnam, Tunisia, Zambia, and Israel.

Experience the quality everyone’s talking about – order today!

D., Cheng, H., Guo, J., Jiang, R.,Zhang, Y., Wan, C., Qin, J., Yuan, G., Chen, S., Yang, Z., Hu, J., Zhang, Y., & Li, W. (2023). 1-year results of dasatinib 70 mg/day versus 100 mg/day in newly diagnosed patients with chronic myeloid leukemia in chronic phase (CML‑CP): A prospective randomized controlled study. Hemasphere, 7(Suppl), e8560105. https://doi.org/10.1097/01.HS9.0000969568.85601.05

Silver, R. T., et al. (2006). Dasatinib (SPRYCEL®) 70 mg twice daily versus other dosing schedules in patients with imatinib-resistant or intolerant CML‑CP: Results from CA180‑034 (START‑C). Blood, 108(11), 166. https://doi.org/10.1182/blood.V108.11.166.166.

Kantarjian, H. M., et al. (2023). Low-dose dasatinib (50 mg daily) frontline therapy in newly diagnosed CML‑CP: 5‑year follow-up results. https://pubmed.ncbi.nlm.nih.gov/37308342/

Satadeve, P. (2025). Comparison of molecular response and safety of lower dose (70 mg) versus standard dose (100 mg) of generic dasatinib in newly diagnosed CML-CP: A randomized controlled study from India. Paper presented at the EHA 2025 Congress. https://www.cml-foundation.org/86-news-icmlf/2333-eha2025-daily-updates-3.html

Shah, N. P., Kantarjian, H., Kim, D.-W., Rea, D., Dorlhiac-Llacer, P., Milone, J. H., ... & Baccarani, M. (2008). Intermittent target inhibition with dasatinib 100 mg once Daily preserves efficacy and improves tolerability in imatinib-resistant and-intolerant chronic-phase chronic myeloid leukemia. Journal of Clinical Oncology, 26(19), 3204–3212. https://doi.org/10.1200/JCO.2007.14.8676